Paolo A. Ascierto, MD, on Melanoma: Sequencing Targeted Treatments and Immunotherapy

September 22, 2020 By The ASCO Post Staff

Paolo A. Ascierto, MD, of the Istituto Nazionale Tumori, discusses phase II results on progression-free survival for patients with advanced melanoma in the SECOMBIT study, whose aim is to evaluate the different sequencing of a BRAF inhibitor (encorafenib) plus a MEK inhibitor (binimetinib) with ipilimumab plus nivolumab (Abstract LBA45).

Related Content